Patients with type 2 diabetes (T2D) frequently have multiple cardiovascular, metabolic, and renal comorbidities, such as hypertension, dyslipidemia, hyperuricemia, chronic kidney disease, and heart failure. Accordingly, this patient population often requires polypharmacy, which is associated with an increased risk of drug-drug interactions, poor adherence, and even adverse outcomes. Accumulating evidence on newer hypoglycemic agents, such as glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors, has highlighted the marked improvements in cardiovascular and renal outcomes associated with the off-target benefits for relevant comorbidities, including hypertension. These classes of hypoglycemic agents are unique, as they achieve consistently modest but significant reductions in systolic and diastolic blood pressure (BP), an effect that has not been targeted and observed with conventional hypoglycemic agents. In addition to this BP-lowering effect, these agents also have multifaceted beneficial impacts on other cardiometabolic and renal parameters, which appear to be helpful for providing an important comprehensive therapeutic approach to improve the prognosis in patients with T2D. The clinical advantages of these agents may reduce the dose and number of concomitant medications used to treat T2D and related comorbidities. These positive spillover effects may also enhance the clinical use of agents to achieve better diabetes care. As a consequence, the clinical significance of these hypoglycemic agents now extends beyond their hypoglycemic effects, thereby providing a new-normal strategy to use in an evidence-based, patient-centric approach to diabetes care.

2型糖尿病（T2D) 经常有多种心血管、代谢和肾脏合并症，如高血压、血脂异常、高尿酸血症、慢性肾病和心力衰竭。因此，该患者群体通常需要多种药物治疗，这与药物-药物相互作用的风险增加、依从性差甚至不良后果有关。越来越多的关于新型降血糖药物的证据，如胰高血糖素样肽 1 受体激动剂和钠-葡萄糖协同转运蛋白 2 抑制剂，强调了心血管和肾脏结局的显着改善与相关合并症（包括高血压）的脱靶益处相关。这些类别的降血糖药是独一无二的，因为它们始终适度但显着降低收缩压和舒张压 ( BP)，这是一种传统降糖药尚未靶向和观察到的效果。除了这种降压作用外，这些药物还对其他心脏代谢和肾脏参数产生多方面的有益影响，这似乎有助于提供一种重要的综合治疗方法来改善 T2D 患者的预后。这些药物的临床优势可能会减少用于治疗 T2D 和相关合并症的伴随药物的剂量和数量。这些积极的溢出效应也可能增强药物的临床使用，以实现更好的糖尿病护理。因此，这些降糖药的临床意义现在超出了它们的降血糖作用，从而提供了一种新的正常策略，可用于以证据为基础、以患者为中心的糖尿病护理方法。